Molecular pathology of pancreatic cancer: from bench-to-bedside translation

Current Drug Targets, 06/01/2012

This depicts a scenario where the identification of novel and effective clinical biomarkers is mandatory. Very recent genome–wide comprehensive studies have shed light on the high degree of genetic complexity and heterogeneity of the pancreatic cancers. Although far from being introduced into the clinical settings, results from those studies are expected to change definitively the perspective through which authors look at the clinical management of pancreatic cancer patients towards a personalized cancer medicine.

Print Article Summary Cat 2 CME Report